Your browser is no longer supported. Please, upgrade your browser.
Settings
ASLN ASLAN Pharmaceuticals Limited daily Stock Chart
ASLN [NASD]
ASLAN Pharmaceuticals Limited
Index- P/E- EPS (ttm)-0.32 Insider Own- Shs Outstand160.25M Perf Week-15.71%
Market Cap567.28M Forward P/E- EPS next Y-1.11 Insider Trans- Shs Float114.29M Perf Month-23.04%
Income- PEG- EPS next Q-0.35 Inst Own10.86% Short Float0.00% Perf Quarter-51.51%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.08 Perf Half Y-56.12%
Book/sh0.26 P/B13.56 EPS next Y27.50% ROA- Target Price11.75 Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.51 - 10.44 Perf YTD-1.67%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-66.09% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low41.04% ATR0.57
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)42.11 Volatility15.14% 16.05%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume2.77 Prev Close3.56
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume19.92K Price3.54
Recom- SMA20-6.04% SMA50-23.57% SMA200-47.97% Volume53,310 Change-0.56%
Jan-14-19Reiterated H.C. Wainwright Buy $12 → $8.50
Jan-14-19 06:34PM  [$$] Aslan Reports Positive Data From Study Combining Its Drug With Chemotherapy The Wall Street Journal
05:44PM  ASLAN Pharmaceuticals to Present Positive varlitinib Data in First-Line Biliary Tract Cancer in Combination With Chemotherapy at ASCO GI GlobeNewswire
09:46AM  ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study Zacks
Jan-13-19 05:30PM  ASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric Cancer GlobeNewswire
Jan-04-19 02:00AM  ASLAN Pharmaceuticals Announces IND Submission for ASLAN003 to U.S. FDA and Conclusion of 30-Day Review Period GlobeNewswire
Jan-02-19 03:48AM  ASLAN Pharmaceuticals Completes Enrolment for Global Pivotal TreeTopp Study Ahead of Schedule GlobeNewswire +15.28%
Dec-02-18 12:00PM  New Data on ASLAN003 Presented at Ash Annual Meeting Shows First Signs of Clinical Activity of a DHODH Inhibitor in Acute Myeloid Leukaemia GlobeNewswire
Nov-27-18 04:47AM  ASLAN Pharmaceuticals Announces Acceptance of Abstracts on New Varlitinib Data in BTC at ASCO Gastrointestinal Cancers Symposium GlobeNewswire
Nov-20-18 05:00AM  Aslan Pharmaceuticals to Participate in 30th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-08-18 06:05AM  ASLAN Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Nov-01-18 10:20AM  ASLAN Pharmaceuticals to Present New Data on ASLAN003 at American Society of Hematology Annual Meeting GlobeNewswire
Oct-30-18 03:54AM  ASLAN Pharmaceuticals Appoints Robert E. Hoffman as Independent Director GlobeNewswire
Oct-22-18 07:00AM  New Data Presented on ASLANs varlitinib at ESMO Show Promising Results in Heavily Pre-Treated BTC and CRC Patients GlobeNewswire
Oct-17-18 12:31PM  ASLAN Pharmaceuticals Enrolls First Subject in Phase 1 Study for ASLAN004 in Atopic Dermatitis GlobeNewswire
Oct-09-18 06:15AM  ASLAN Pharmaceuticals to Present Posters on Varlitinib and ASLAN003 at European Society for Medical Oncology Congress GlobeNewswire
Sep-21-18 04:00AM  ASLAN Pharmaceuticals Presents Two Posters on Varlitinib at Chinese Society of Clinical Oncology Annual Meeting GlobeNewswire
Sep-17-18 06:58AM  ASLAN Pharmaceuticals Provides Update on Timelines for Clinical Trial of Varlitinib in Biliary Tract Cancer in China GlobeNewswire
Sep-04-18 02:47AM  ASLAN Pharmaceuticals to Present at HC Wainwright 20th Annual Global Investment Conference GlobeNewswire
Aug-20-18 02:49AM  ASLAN Pharmaceuticals Granted Orphan Drug Designation by the FDA for ASLAN003 for the Treatment of Acute Myeloid Leukaemia GlobeNewswire
Aug-10-18 08:19AM  ASLAN Pharmaceuticals Completes Recruitment for Global Phase 2 Study for Varlitinib in First Line Gastric Cancer GlobeNewswire
Aug-06-18 04:05AM  ASLAN Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Jul-03-18 04:01AM  ASLAN Pharmaceuticals Submits Clinical Trial Authorisation Application for First in Man Studies for ASLAN004 GlobeNewswire
May-30-18 01:47PM  Analysts Roar Praise For Aslan, But Leerink More Tepid Benzinga +34.45%
08:35AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
May-17-18 02:25AM  ASLAN Pharmaceuticals to Present Two Posters on Varlitinib at ASCO GlobeNewswire
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in developing therapeutics for global markets. It targets diseases that are highly prevalent in Asia, and orphan indications in the United States and Europe. The company's product pipeline includes Varlitinib, a reversible small molecule pan-human epidermal growth factor receptor inhibitor that is being studied in global pivotal trials (TreeTopp) for biliary tract cancer, and conducting Phase 2/3 clinical trials for gastric cancer, as well as testing in a single-arm pivotal clinical trial in biliary tract cancer in China. It has exclusive global rights to develop, manufacture, and commercialize varlitnib for all human and animal therapeutic, diagnostic, and prophylactic uses. It is also developing ASLAN003, an orally active potent inhibitor of human dihydroorotate dehydrogenase that is in Phase 2 clinical trails to treat acute myeloid leukemia; and ASLAN004, an interleukin 4/interleukin 13 receptor antibody for the treatment of severe atopic dermatitis and asthma. The company has partnerships with Array BioPharma, Bristol-Myers Squibb, Almirall, and CSL. ASLAN Pharmaceuticals Limited was founded in 2010 and is headquartered in Singapore.